Last reviewed · How we verify
Pseudomonas Aeruginosa Biliary Tract Infection
Approved treatments
- Ramycin
Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins. - Garamycin · Merck & Co.
- Gentamicin · Merck & Co.
- Arikayce Kit · Bristol-Myers Squibb
Amikacin works by binding to bacterial ribosomes, inhibiting protein synthesis and ultimately killing the bacteria.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Pseudomonas Aeruginosa Biliary Tract Infection patent landscape — cliff calendar, originator estates, attackable patents
- Pseudomonas Aeruginosa Biliary Tract Infection treatment landscape brief
- Pseudomonas Aeruginosa Biliary Tract Infection treatment updates RSS
Frequently asked questions about Pseudomonas Aeruginosa Biliary Tract Infection
What drugs treat Pseudomonas Aeruginosa Biliary Tract Infection?
Tracked treatments include Ramycin, Garamycin, Gentamicin, Arikayce Kit.
What is the treatment for Pseudomonas Aeruginosa Biliary Tract Infection?
Standard treatment for Pseudomonas Aeruginosa Biliary Tract Infection includes Ramycin, Garamycin, Gentamicin, Arikayce Kit. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Pseudomonas Aeruginosa Biliary Tract Infection patent cliff · Pseudomonas Aeruginosa Biliary Tract Infection CI report
- Treatment: Ramycin
- Treatment: Garamycin · Merck & Co.
- Treatment: Gentamicin · Merck & Co.
- Treatment: Arikayce Kit · Bristol-Myers Squibb
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing